EZH2型
上皮-间质转换
癌症研究
组蛋白甲基转移酶
组蛋白H3
生物
蛋白激酶B
分子生物学
化学
细胞生物学
染色质
信号转导
下调和上调
生物化学
基因
DNA
作者
Xiaoxu Zhou,Chongxiang Xiong,Evelyn Tolbert,Ting C. Zhao,George Bayliss,Shougang Zhuang
标识
DOI:10.1096/fj.201800237r
摘要
Enhancer of zeste homolog-2 (EZH2) is a methyltransferase that induces histone H3 lysine 27 trimethy- lation (H3K27me3) and functions as an oncogenic factor in many cancer types. Its role in renal epithelial mesenchymal transition (EMT) remains unknown. In this study, we found that EZH2 and H3K27me3 were highly expressed in mouse kidney with unilateral ureteral obstruction and cultured mouse kidney proximal tubular (TKPT) cells undergoing EMT. Inhibition of EZH2 with 3-deazaneplanocin A (3-DZNeP) attenuated renal fibrosis, which was associated with preserving E-cadherin expression and inhibiting Vimentin up-regulation in the obstructed kidney. Treatment with 3-DZNeP or transfection of EZH2 siRNA also inhibited TGF-β1-induced EMT of TKPT cells. Injury to the kidney or cultured TKPT cells resulted in up-regulation of Snail family transcriptional repressor 1 (Snail-1) and Twist family basic helix-loop-helix (BHLH) transcription factor 1 (Twist-1), which are 2 transcription factors, and down-regulation of phosphatase and tensin homolog, a protein tyrosine phosphatase associated with inhibition of PI3K-protein kinase B (AKT) signaling; EZH2 inhibition or silencing reversed all those responses. 3-DZNeP was also effective in suppressing epithelial arrest at the G2/M phase and dephosphorylating AKT and β-catenin in vivo and in vitro. These data indicate that EZH2 activation contributes to renal EMT and fibrosis through activation of multiple signaling pathways and suggest that EZH2 has potential as a therapeutic target for treatment of renal fibrosis.—Zhou, X., Xiong, C., Tolbert, E., Zhao, T. C., Bayliss, G., Zhuang, S. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and at tenuates renal fibrosis. 32, 5976–5989 (2018). www.fasebj.org
科研通智能强力驱动
Strongly Powered by AbleSci AI